产品
编 号：F153194
分子式：C16H25N3O5S
分子量：371.45
分子式：C16H25N3O5S
分子量：371.45
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 141064-23-5
产品详情
生物活性：
Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease.
体内研究：
Xanomeline oxalate 强烈刺激体内 PI 水解，并且该作用被毒蕈碱拮抗剂阻断，表明由毒蕈碱受体介导。在小鼠中，Xanomeline oxalate 诱导的海马体中 [3H]-IP 积累的 ED100 在为 54 μMole/kg。在大鼠中，Xanomeline oxalate 诱导的海马体中 [3H]-IP 积累的 ED100 为 8.1 μMole/kg。Animal Model:Male CF1 mice weighing 18-20 g are injected [3H]-myoinositol
Dosage:8.1-81 μmole/kg
Administration:S.c. injections; 1 h prior to killing and 1 h after the administration
Result:Increased accumulation in a dose-related manner up to 130%, 75%, 60% above lithium levels in hippocampus, cortex and neostriatum, respectively. And did not increase accumulation of [3H]-IP in the brain stem.Induced salivation, tremor and hypothermia in mice with the ED50 of 13.7±0.8 μmole/kg.
Animal Model:Rats are injected [3H]-myoinositol
Dosage:2.7-81 μmole/kg
Administration:S.c. injections; 1 h prior to killing and 1 h after the administration
Result:Increased [3H]-IP formation dose dependently in hippocampus up to 221% above lithium control.
体外研究：
Xanomeline oxalate 刺激 A9 L m1 细胞中的磷酸肌醇 (PI) 水解。 Xanomeline oxalate 抑制[3H]-pirenzepine ([3H]-PZ) 和[3H]-oxotremorine-M ([3H]-OXO-M) 结合大鼠大脑的 Ki 分别为 7 和 3 nM。
Xanomeline oxalate (LY246708 oxalate) is a potent and selective muscarinic receptor agonist (SMRA) and stimulates phosphoinositide hydrolysis in vivo. Xanomeline oxalate can be used for the research of Alzheimer’s disease.
体内研究：
Xanomeline oxalate 强烈刺激体内 PI 水解，并且该作用被毒蕈碱拮抗剂阻断，表明由毒蕈碱受体介导。在小鼠中，Xanomeline oxalate 诱导的海马体中 [3H]-IP 积累的 ED100 在为 54 μMole/kg。在大鼠中，Xanomeline oxalate 诱导的海马体中 [3H]-IP 积累的 ED100 为 8.1 μMole/kg。Animal Model:Male CF1 mice weighing 18-20 g are injected [3H]-myoinositol
Dosage:8.1-81 μmole/kg
Administration:S.c. injections; 1 h prior to killing and 1 h after the administration
Result:Increased accumulation in a dose-related manner up to 130%, 75%, 60% above lithium levels in hippocampus, cortex and neostriatum, respectively. And did not increase accumulation of [3H]-IP in the brain stem.Induced salivation, tremor and hypothermia in mice with the ED50 of 13.7±0.8 μmole/kg.
Animal Model:Rats are injected [3H]-myoinositol
Dosage:2.7-81 μmole/kg
Administration:S.c. injections; 1 h prior to killing and 1 h after the administration
Result:Increased [3H]-IP formation dose dependently in hippocampus up to 221% above lithium control.
体外研究：
Xanomeline oxalate 刺激 A9 L m1 细胞中的磷酸肌醇 (PI) 水解。 Xanomeline oxalate 抑制[3H]-pirenzepine ([3H]-PZ) 和[3H]-oxotremorine-M ([3H]-OXO-M) 结合大鼠大脑的 Ki 分别为 7 和 3 nM。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备